Certara (CERT) vs OptimizeRx (OPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Certara (CERT) has outperformed OptimizeRx (OPRX) over the past year, losing 33.5% versus a loss of 54.1%. Over five years, CERT leads with a -77.2% price change compared with -90.1% for OPRX. Certara is the larger company by market cap ($1.32 billion vs $157.8 million), about 8.3 times the size.
On valuation, OptimizeRx trades at a lower forward P/E (8.0x vs 22.2x for Certara).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERT | OPRX |
|---|---|---|
| Share price | $8.64 | $8.38 |
| Market cap | $1.32B | $157.85M |
| 1-day change | -3.57% | -1.99% |
| YTD return | -1.93% | -31.65% |
| 1-year return | -33.54% | -54.06% |
| 5-year return | -77.17% | -90.10% |
| P/E ratio (TTM) | — | 34.92 |
| Forward P/E | 22.17 | 8.03 |
| EPS (TTM) | $-0.13 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.11 | $22.25 |
| 52-week low | $4.45 | $4.54 |
| Distance from 52-week high | -34.10% | -62.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +0.81% | +50.36% |
| Average volume | 3.10M | 203.38K |
| Shares outstanding | 152.54M | 18.84M |
| Employees | 1,515 | 132 |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Health Information Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Certara is about 8.3 times larger than OptimizeRx by market value ($1.32B vs $157.85M).
- CERT has outperformed OPRX by 20.5 percentage points over the past year.
About Certara
CERT stock →Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Healthcare · Health Information Services · 1,515 employees
About OptimizeRx
OPRX stock →OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail.
Healthcare · Health Information Services · 132 employees
CERT vs OPRX FAQ
Which is bigger, Certara or OptimizeRx?
Certara (CERT) is larger, with a market capitalization of $1.32B compared with $157.85M for OptimizeRx (OPRX).
Which stock has performed better over the past year, CERT or OPRX?
CERT returned -33.54% over the past 12 months, compared with -54.06% for OPRX (price return, excluding dividends). Past performance does not predict future results.
Are Certara and OptimizeRx in the same industry?
Yes. Both are classified in the Health Information Services industry within the Healthcare sector.